BioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals

Benzinga Newsdesk www.benzinga.com Neutral 93.2%

Neg 0% Neu 93.2% Pos 0%

https://www.sec.gov/Archives/edgar/data/1776985/000177698526000061/a991260828_bntxxcrcxenxfin.htm

Comments

No comments yet. Be the first!